6533b837fe1ef96bd12a3203

RESEARCH PRODUCT

Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs

Silvia WeinRainer CermakPeter LangguthSiegfried Wolffram

subject

MaleSimvastatinStatinFlavonolsSwinemedicine.drug_classBiological AvailabilityPharmaceutical SciencePharmacologyFood-Drug Interactionschemistry.chemical_compoundPharmacokineticsBlood plasmapolycyclic compoundsmedicineAnimalsIngestionheterocyclic compoundscardiovascular diseasesCross-Over StudiesbiologyChemistrynutritional and metabolic diseasesBioavailabilitySimvastatinHMG-CoA reductasebiology.proteinQuercetinlipids (amino acids peptides and proteins)Quercetinmedicine.drug

description

The influence of the dietary flavonol quercetin on the pharmacokinetics of the HMG-CoA reductase inhibitor simvastatin was investigated in pigs. Simvastatin (0.25mg/kg body weight) was orally administered to six pigs either without or with quercetin (10mg/kg). In addition, simvastatin was administered to three pigs that had received a diet supplemented with the flavonol over a period of 1 week. Daily quercetin intake was 10mg/kg in these animals. Co-ingestion of quercetin with the statin did not alter area under the concentration time curve (AUC(0-->infinity)), time to achieve maximum plasma concentration (t(max)) or half-life (t(1/2)) of simvastatin. However, there was a trend towards a reduction of the maximum plasma concentration (C(max)) of simvastatin when quercetin was administered concomitantly (P=0.06). As compared to controls, AUC(0-->infinity) of simvastatin was significantly decreased after feeding the quercetin-supplemented diet for 1 week. The plasma ratio of simvastatin and its acid metabolite was neither altered by the concomitant quercetin ingestion nor by feeding of the flavonol over a period of 1 week. We conclude that chronic ingestion of high doses of the flavonol quercetin will decrease the bioavailability of simvastatin to a significant extent.

https://doi.org/10.1016/j.ejps.2009.09.018